Current treatment options for human stroke are limited mainly to the modestly effective infusion of tissue plasminogen activator (tPA), with additional improvement of functional independence and higher rates of angiographic revascularization observed after mechanical thrombectomy. However, new therapeutic strategies that address post-stroke immunemediated inflammatory responses are urgently needed. Recent studies in experimental stroke have firmly implicated immune mechanisms in the propagation and partial resolution of central nervous system damage after the ischaemic event. A new-found anti-inflammatory role for regulatory B (Breg) cells in autoimmune diseases sparked interest in these cells as potential immunomodulators in stroke. Subsequent studies identified interleukin-10 as a common regulatory cytokine among all five of the currently recognized Breg cell subsets, several of which can be found in the affected brain hemisphere after induction of experimental stroke in mice. Transfer of enriched Breg cell subpopulations into both B-cell-depleted and wild-type mice confirmed their potent immunosuppressive activities in vivo, including recruitment and potentiation of regulatory T cells. Moreover, Breg cell therapy strongly reduced stroke volumes and treatment outcomes in ischaemic mice even when administered 24 hr after induction of experimental stroke, a treatment window far exceeding that of tPA. These striking results suggest that transfer of enriched Breg cell populations could have therapeutic value in human stroke, although considerable clinical challenges remain.
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Transfer of enriched Breg cell subpopulations into both B-cell-depleted and wild-type mice confirmed their potent immunosuppressive activities in vivo, including recruitment and potentiation of regulatory T cells. Moreover, Breg cell therapy strongly reduced stroke volumes and treatment outcomes in ischaemic mice even when administered 24 hr after induction of experimental stroke, a treatment window far exceeding that of tPA. These striking results suggest that transfer of enriched Breg cell populations could have therapeutic value in human stroke, although considerable clinical challenges remain.
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Stroke and the immune response
Stroke is the fifth leading cause of death and the leading cause of disability in the USA, affecting up to 795 000 individuals a year. 1 Worldwide, 15 million individuals experience a stroke, resulting in 5 million deaths and another 5 million individuals left with permanent disabilities. Despite intensive efforts to find better therapeutics, the only drug approved to treat ischaemic stroke is recombinant tissue plasminogen activator (tPA), which must be administered within 4Á5 hr of the stroke event but fails to treat haemorrhagic stroke. tPA was given US Food and Drug Administration approval in 1996. 2 More recent studies using mechanical thrombectomy + tPA have shown additional benefit, providing better functional outcomes, lower mortality and more successful recanalization, 3, 4 but do not address immune-mediated tissue damage.
Stroke research has become increasingly focused on the immune response to brain injury after a stroke. Animal models of stroke have clearly demonstrated that approaches that modulate the immune system after induction of experimental stroke can be neuroprotective. Splenectomy, which removes a large reservoir of
potentially damaging immune cells, reduces infarct volume when performed 2 weeks before induction of experimental stroke. [5] [6] [7] [8] [9] After stroke induction, however, the spleen undergoes a massive reduction in size and cellularity that mirrors the onset of immunosuppression in mice, 10 rats 11 and stroke patients, [12] [13] [14] which may account for increased risk of life-threatening infections.
Evaluation of cellular and humoral immune responses after induction of experimental stroke has identified both pathological and protective cytokines and cell types. Studies using immune cell-specific knockout mice have revealed which cells are detrimental and even which cells are protective after stroke. Mice that lack lymphocytes (Rag À/À or SCID mice) have significantly smaller infarcts compared with wild-type (WT) mice. 15, 16 The depletion of T cells, both CD4 + and CD8 + subsets, significantly reduced infarct volumes, whereas depletion of B cells had no effect on infarct volumes 24 hr after stroke induction. 15 This suggests that T cells, but not B cells, might contribute to post stroke neural injury. When B cells were examined more specifically, it was found that B-cell knockout mice (lMT À/À ) had larger infarcts than WT mice, 17 suggesting that B cells could be playing a protective role in limiting detrimental neuroinflammation. In particular, a B-cell subset, regulatory B (Breg) cells, has been shown to be protective in experimental stroke.
Regulatory B cells in autoimmune diseases
Regulatory B cells are a subset of B cells that secrete interleukin-10 (IL-10) and have anti-inflammatory effects on T cells, macrophages, natural killer cells and dendritic cells. Research on Breg cells has been hampered by the lack of a single cell-specific marker or a signature transcription factor such as FoxP3 in the case of regulatory T (Treg) cells. To date, there are at least seven different subsets of Breg cells, including two immature Breg cell types and five mature Breg cell types. All Breg cells secrete IL-10 18, 19 and most are found within the spleen, with the exception of plasma cells that are found in the lymph nodes. As is illustrated in Fig. 1 22 by dampening pro-inflammatory T cells and enhancing the expansion of Treg cells. 23 In CIA, specifically IL-10-producing B cells were found to be protective, whereas B cells from IL-10 À/À mice did not provide any protection against CIA. Moreover, transfer of different Breg subsets into CIA-affected mice demonstrated that only the T2-MZP Breg subpopulation could protect the recipient mice from CIA disease progression. 24 In systemic lupus erythematous, susceptible NZB/W F 1 mice were found to have increased disease progression when B cells were depleted at 4 weeks of age but not if B cells were depleted at later time-points. 25 This observed exacerbation of lupus-like disease was associated with expansion of B10 Breg cells that occurred at~4 weeks of age as was found in C57BL/6 mice. 25, 26 In diabetes, transfer of activated B cells into disease-susceptible NOD mice reduced the incidence of diabetes, whereas this effect was not present in B cells from IL-10 À/À mice. Furthermore, transfer of activated B cells into NOD mice correlated with CD4 + T-cell polarization towards an anti-inflammatory Th2 activation state, with reduced activation of pro-inflammatory Th1 cells. 27 In the EAE model of multiple sclerosis, B-cell depletion before disease induction resulted in increased clinical severity, whereas reconstitution with B cells from WT but not IL-10 À/À mice conferred protection, 28,29 a pattern similar to that observed in other autoimmune diseases. Other studies demonstrated that B cells played a role in EAE disease initiation but that Breg cells, particularly B10 cells, could down-regulate activation of encephalitogenic T cells and reduce ongoing disease severity. 26 Our own studies demonstrated that the strongly protective effect of oestrogen pretreatment on EAE induction [30] [31] [32] was mediated in large part by IL-10-producing Breg cells. We found that oestrogen-treated B-cell-deficient lMT À/À mice were not protected from EAE, 33 whereas transfer of WT IL-10-producing B cells before oestrogen administration could protect the recipient WT mice from subsequent EAE induction. 34 Moreover, oestrogen treatment was found to induce B10 (CD5 + CD1d hi ), Tim-1 + Breg cells and (CD138 + CD44 hi ) Breg cell plasmablasts in the EAE protected mice. 35 It is this protective role in autoimmune diseases, particularly EAE, that prompted investigation into whether Breg cells could also modulate the immune system after stroke to protect the brain from increased neuroinflammation and neural injury.
Regulatory B cells in stroke
It is now well established that human stroke results in multi-organ systemic disease rather than being restricted solely to the infarcted region of the brain. In animals, focal brain ischaemia induces systemic changes in the immune system that can lead to immune dysfunction. Although the immune system can become suppressed in response to pathogens, it becomes highly pro-inflammatory towards the injured brain. The spleen, a reservoir of immune cells, is affected by cerebral ischaemia in mice, rats and stroke patients. 5, [10] [11] [12] Splenic activation leads to expulsion of immune cells into the blood that then migrate to the brain. 11 These immune cells probably exacerbate the evolving brain infarct, enhancing neural injury. However, data suggest that some types of immune cells may have favourable effects on the injured brain and provide a type of natural central nervous system (CNS) protection.
Recent studies have identified a small but powerful subset of IL-10-producing CD5 + CD1d hi Breg cells (B10) that can limit CNS inflammation and clinical signs of neurological disease in rodent experimental models. 36 Depletion of B cells, including the B10 subset (B-cell-deficient mice or depletion with anti-CD22 monoclonal antibody) causes increased disease severity in EAE models and transfer of the CD5 + CD1d hi (B10) Breg subset can provide protection against EAE disease induction. B-celldeficient mice have a significant increase in cortical infarction after middle cerebral artery occlusion (MCAO), implicating protective regulatory effects by B cells (Fig. 2a) . Transfer of 50 million B cells intraperitoneally into B-cell knockout mice 24 hr before MCAO reduced infarct volume, yet B cells transferred from IL-10 À/À mice did not affect infarct size. 17 The ability of the B10 subset to limit CNS injury probably resides in these cells' marked secretion of IL-10 (as discussed above), a wellrecognized anti-inflammatory cytokine that is effective against most forms of CNS damage. These findings strongly support the need to further evaluate the role of Breg cells in stroke.
In mice there is a drastic loss of immune cells in the spleen accompanied by a pronounced increase in Treg cells within days of the ischaemic insult. In normal mice, Treg cells limit inflammation and inhibit autoimmune diseases. [37] [38] [39] [40] Based on our observed increases in surviving CD3 + CD4 + CD25 + FoxP3 + Treg cells, 10 it seemed that these cells were relatively resistant to apoptosis or other mechanisms that act to reduce viable immune splenocyte numbers. However, within the literature there are mixed results regarding the role of Treg cells after stroke and their ability to limit inflammation within the ischaemic brain. 41 A number of reports suggested a protective role of Treg cells in stroke, 42 whereas our earlier study using conditional FoxP3 knockout mice demonstrated CD4 + CD25 + FoxP3 + Treg cells did not contribute significantly in limiting infarct volume after MCAO. 43 Alternatively, Breg cell subsets might play a crucial regulatory role that limits post CNS injury and neuroinflammation.
In mice, total spleen and blood cell numbers are reduced~90% by 96 hr after MCAO. However, B cells still constitute~30% of the remaining mononuclear cells. 10 Infarct volumes were increased after MCAO in Bcell-deficient mice and a report in stroke patients showed worse clinical outcome when patients had lower circulating levels of B cells. 44 Enter the timely reports of Breg cells [45] [46] [47] and the newly described regulatory IL-10-secreting B-cell subset, called B10. 48 These Breg cells were found to have powerful inhibitory effects on other experimental inflammatory diseases, including EAE and murine lupus 26,49,50 as described above. A key function of B10 cells is their secretion of IL-10, an anti-inflammatory cytokine that has been studied extensively in stroke. 51 Indeed, IL-10-deficient mice developed larger infarcts after permanent focal ischaemia. 52 Conversely, administration of exogenous IL-10 to the lateral ventricle, 53 intraperitoneally in combination with hypothermia, 54 by adenoviral vectors, 55 after induction of mucosal tolerance by IL-10-producing myelin oligodendrocyte glycoproteinreactive T cells 56 or by transgenic over-expression of IL-10 57 all reduced infarct volumes. Moreover, IL-10 prevented neuronal damage induced by excitotoxicity in vitro. 52 Clinically, early worsening of stroke was associated with lower IL-10 plasma levels in patients. 58 Conversely, excessive circulating levels of IL-10 may predispose to increased infections. 59 Taken together, these findings suggest that local secretion of IL-10 may be preferable to systemic delivery.
We found that total CD19 + B cells were modestly increased in the CNS and periphery 48 hr after MCAO. Of key importance, the CD5 + CD1d hi B10 cell subset was highly enriched in the ipsilateral versus contralateral hemispheres of MCAO mice at this early time-point (36Á7% versus 13Á4% of CD19 + B cells), so establishing the presence of this potentially important regulatory Bcell subtype in the affected CNS infarcted region during stroke. 60 Moreover, MCAO also induced an increased percentage of IL-10-secreting B cells in blood, demonstrating the availability of circulating Breg cells for entry into the CNS. Although these MCAO induced Breg cells may have limited CNS damage, they clearly were not sufficient to prevent it. Hence, passive transfer studies were carried out to increase Breg cell numbers before or just after MCAO induction. Stereotaxic delivery of B cells, including IL-10-producing Breg cells, to the affected hemisphere significantly decreased the infarct volume. 60 To more efficiently track the Breg cells, IL-10-producing cells that expressed green fluorescent protein (GFP) were used as donor cells. Hence, B cells were isolated from splenocytes obtained from IL-10 GFP reporter mice and were primed with lipopolysaccharide for 48 hr to enhance IL-10 production. Five million IL-10-producing B cells were transferred intravenously to lMT À/À mice and 24 hr later recipients were subjected to 60 min of MCAO via intraluminal filament (Fig. 3) followed by 48 hr of reperfusion. Compared with vehicle-treated controls, the IL-10 + B-cellreplenished lMT À/À mice had reduced infarct volumes ( Fig. 2b ) and fewer infiltrating T cells and activated monocytes (CD11b + CD45 hi ) in the affected brain hemisphere. Hence, the improvement in stroke outcome could be attributed to significant reduction in infiltrating immune cells into the brain and/or the reduction in proinflammatory mediators. Breg-mediated reduction in infarct volumes reduced ischaemia-related splenic atrophy, resulting in increased spleen cell numbers (Fig. 2c) accompanied by lower levels of pro-inflammatory mediators and reduced activation status (CD69 and CD44 expression by CD4 + T cells) of the surviving splenic T cells and monocytes. This observation implicated a novel connection between the ischaemic lesion in brain and evolving inflammatory changes in distant peripheral immune cell populations. Not only could the IL-10 + B cells attenuate pro-inflammatory responses, but they also significantly enhanced other Treg cell subsets (ie. CD4 + Foxp3 + and CD8 + CD122 + Treg cells) in the periphery. These novel observations were the first to implicate the IL-10-producing capacity of B cells as a major regulatory mediator in stroke. 36 Interleukin-10-producing Breg cells potentially could impart significant benefit for stroke patients in the clinic. Hence, therapeutic strategies were explored for the treatment of MCAO in mice. Interleukin-10-producing Breg cells were transferred into B-cell-sufficient WT C57BL/6J mice. Five million IL-10-producing B cells, obtained from IL-10 GFP reporter mice were transferred intravenously to WT mice 24 hr before 60 min of MCAO followed by 96 hr of reperfusion. The IL-10 + B cells that were transferred into the mice were composed of primarily B10 cells, B-1a cells and T2-MZP cells (16Á42%, 17Á53% and 13Á06%, respectively) (Fig. 3) . Compared with vehicletreated controls, the IL-10 + B-cell-pretreated WT mice had reduced infarct volumes (Fig. 4a) . Reduction in infarct volumes also promoted a reduction in ischaemiarelated splenic atrophy (Fig. 5a ) accompanied by lower pro-inflammatory (tumour necrosis factor and IL-17 (mean AE SEM). Significant differences between the groups were determined using Student's t-test (*P ≤ 0Á05, **P ≤ 0Á01 and ***P ≤ 0Á001). Republished with permission by Bodhankar et al., (Fig. 6) .
Further studies successfully demonstrated a therapeutic role of IL-10 + B cells in stroke. IL-10 + B cells transferred to WT mice 4 hr after MCAO significantly reduced infarct volume compared with vehicle-treated recipient mice (Fig. 4b) . Remarkably, transfer of IL-10 + Breg cells 4 hr after MCAO induction in WT recipient mice reduced infarct volumes more than transfers given 24 hr before MCAO. These results clearly indicate the potent immunoregulatory role of the IL-10 + B cells as they potentially regulate the native B-cell population to generate a more favourable milieu to alleviate stroke outcome. 61 A subsequent study established an effective therapeutic time-point as late as 24 hr after MCAO in B-cell-sufficient male WT mice. IL-10 + Breg-cell-treated mice had significantly reduced infarct volumes (Fig. 4c) and improved neurological deficits versus vehicle-treated control mice after 60 min occlusion and 96 hr of reperfusion. The MCAO-protected Breg-cell-recipient mice had less splenic atrophy (Fig. 5b) and reduced numbers of activated, inflammatory T cells, decreased infiltration of T cells and a less inflammatory milieu in the ischaemic hemispheres compared with vehicle-treated control independent experiments with spleens processed from nine or ten individual mice (mean AE SEM). Significant differences between the groups were determined using Student's t-test and are indicated (*P ≤ 0Á05 and **P ≤ 0Á01). Republished with permission by Bodhankar et al., 62 p. 918, mice. 62 These immunoregulatory changes occurred in concert with the predominant appearance of IL-10 secreting CD8 + CD122 + Treg cells in both the spleen (Fig. 7 ) and the MCAO-affected brain hemisphere (Fig. 8) . 62 This study demonstrates a major neuroprotective role for IL-10 + B cells in treating MCAO in male WT mice at a time-point as late as 24 hr post-stroke leading to the generation of an additional highly potent regulatory subset (IL-10 + CD8 + CD122 + Treg cells), which in turn appears to play a dominant role in attenuating pro-inflammatory reactions generated upon reperfusion-based cerebral injury.
Conclusion
Regulatory B cells have been demonstrated to play a protective role in treating stroke, due largely to their ability to secrete IL-10, which modulates the post-stroke immune response and to up-regulate and recruit IL-10-secreting Treg cells into the injured brain. Local delivery of IL-10 and recruitment of Treg cells within the infarcted brain regions can then reduce pro-inflammatory cells and cytokines that mediate neural injury. Additionally, Breg cells have the ability to extend the current therapeutic window for treating stroke from 4Á5 hr to 24 hr. Treatment with Breg cells consistently reduces infarct volumes and improves neurological function compared with WT mice after experimental stroke, so demonstrating unique therapeutic potential. Continued research into the role of Breg cells in limiting post stroke immune-mediated neural injury will be required to ensure that Breg cells do not further suppress protective immune responses known to be impaired after stroke. Moreover, depending upon the source and proliferative potential of transferred Breg cells to stroke patients, it may be useful to introduce 'safety switches' to allow selective elimination of the cells 63 as well as methods to prevent the possibility of cytokine release syndrome. 64 Finally, given the potential protective versus infective functions of the microbiome on stroke outcomes, 65, 66 modulating the effects of microbial products on Breg cell functions may need to be considered to achieve successful long-term stroke therapy.
